Back to results
US 6,797,269 B2Granted
Mesenchymal stem cells as immunosuppressants
AssigneeOsiris Therapeutics, Inc.
InventorsJoseph D. Mosca, Kevin R. McIntosh
Life of this patent
Estimating the term…
Abstract
The present invention provides a method to modulate immune responses using antigen presenting human mesenchymal stem cells to induce specific T cell anergy. The present invention also provides a method to modulate immune responses using human mesenchymal stem cells as a platform to express molecules which will induce T cell anergy.
Claims16
A method of inhibiting a T-cell response to an antigen, comprising;
- culturing mesenchymal stem cells in the presence of IFN-γ;
- modifying said mesenchymal stem cells to present said antigen by contacting said mesenchymal stem cells with said antigen in vitro, wherein said mesenchymal stem cells do not produce co-stimulatory molecules in a sufficient amount to activate T-cells, whereby said mesenchymal stem cells present said antigen;
- and
- administering to a host said modified mesenchymal stem cells, thereby inhibiting a T-cell response to said antigen upon subsequent exposure of the T-cells to antigen presenting cells which express co-stimulatory molecules.
1 more element
A method of inhibiting a T-cell response to an antigen, comprising:
- culturing mesenchymal stem cells in the presence of IFN-γ;
- modifying human mesenchymal stem cells to present said antigen by genetically engineering said human mesenchymal stem cells to express said antigen, wherein said human mesenchymal stem cells do not produce co-stimulatory molecules in a sufficient amount to activate T-cells, whereby said human mesenchymal stem cells present said antigen;
- and
- administering to a host said modified human mesenchymal stem cells, thereby inhibiting a T-cell response to said antigen upon subsequent exposure of the T-cells to antigen presenting cells which express co-stimulatory molecules.
1 more element
Dependencies are inferred from the claim text.